Global Pharmaceuticals & Biotech Top Stock Picks from Analysts

Neurizon Therapeutics

Market Cap: AU$73.8m

A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases.

Sona Nanotech

Market Cap: CA$66.5m

Operates as a nanotechnology life sciences company.

Magle Chemoswed Holding

Market Cap: SEK 446.0m

Engages in research and development of pharmaceutical and medical device products in Sweden.

FibroGen

Market Cap: US$45.7m

A biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.

Lantern Pharma

Market Cap: US$45.4m

Focuses on the discovery and development of oncology drug.

Covalon Technologies

Market Cap: CA$62.5m

Engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally.

Plus Therapeutics

Market Cap: US$44.6m

A clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.

Annovis Bio

Market Cap: US$44.4m

A clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.

CalciMedica

Market Cap: US$44.3m

A clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage.

Jasper Therapeutics

Market Cap: US$43.7m

A clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.

RenovoRx

Market Cap: US$43.6m

A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.

Jupiter Neurosciences

Market Cap: US$43.5m

A clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation.

Radiopharm Theranostics

Market Cap: AU$66.2m

Engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.

AlzeCure Pharma

Market Cap: SEK 405.6m

Operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system.

Intervacc

Market Cap: SEK 401.5m

Develops novel veterinary vaccines for animals in Sweden.

Medical Developments International

Market Cap: AU$64.8m

Manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally.

Grace Therapeutics

Market Cap: US$42.3m

Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.

PepGen

Market Cap: US$42.0m

A clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.

Marinomed Biotech

Market Cap: €35.6m

A biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally.

Genetic Signatures

Market Cap: AU$63.6m

Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.

Sernova Biotherapeutics

Market Cap: CA$57.5m

Operates as a clinical-stage biotechnology company in Canada.

Century Therapeutics

Market Cap: US$41.4m

A clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.

Acrivon Therapeutics

Market Cap: US$40.9m

A clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.

Malin

Market Cap: €34.6m

Through its subsidiaries, operates in the life sciences industry in Ireland and the United States.

Generation Bio

Market Cap: US$40.3m

A biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells.

Estrella Immunopharma

Market Cap: US$40.0m

A clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.

Telomir Pharmaceuticals

Market Cap: US$40.0m

A preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases.

IGC Pharma

Market Cap: US$39.8m

A clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia.

Outlook Therapeutics

Market Cap: US$39.5m

Operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.

Futura Medical

Market Cap: UK£29.0m

Research, develops, and commercializes pharmaceutical and healthcare products for sexual health.

ZYUS Life Sciences

Market Cap: CA$53.9m

Manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union.

Mendus

Market Cap: SEK 364.6m

A biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors.

Pluri

Market Cap: US$38.2m

A biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries.

Navamedic

Market Cap: NOK 381.5m

A pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally.

Xilio Therapeutics

Market Cap: US$37.2m

A clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies.

Poolbeg Pharma

Market Cap: UK£27.4m

A clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom.